CN116920030A - Traditional Chinese medicine composition for treating diabetic peripheral neuropathy qi deficiency and blood stasis - Google Patents
Traditional Chinese medicine composition for treating diabetic peripheral neuropathy qi deficiency and blood stasis Download PDFInfo
- Publication number
- CN116920030A CN116920030A CN202310552511.3A CN202310552511A CN116920030A CN 116920030 A CN116920030 A CN 116920030A CN 202310552511 A CN202310552511 A CN 202310552511A CN 116920030 A CN116920030 A CN 116920030A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- rhizoma
- medicine composition
- deficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 210000004369 blood Anatomy 0.000 title claims abstract description 28
- 239000008280 blood Substances 0.000 title claims abstract description 28
- 230000007812 deficiency Effects 0.000 title claims abstract description 27
- 208000032131 Diabetic Neuropathies Diseases 0.000 title claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 27
- 239000003826 tablet Substances 0.000 claims abstract description 17
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 241000132012 Atractylodes Species 0.000 claims abstract description 10
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 9
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims description 14
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000000643 oven drying Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 241000213006 Angelica dahurica Species 0.000 claims 1
- 244000170916 Paeonia officinalis Species 0.000 claims 1
- 239000003655 absorption accelerator Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 42
- 208000024891 symptom Diseases 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 15
- 230000001953 sensory effect Effects 0.000 abstract description 15
- 241000382455 Angelica sinensis Species 0.000 abstract description 8
- 241000736199 Paeonia Species 0.000 abstract description 8
- 230000007830 nerve conduction Effects 0.000 abstract description 8
- 206010041956 Stasis syndrome Diseases 0.000 abstract description 7
- 208000005634 blind loop syndrome Diseases 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 5
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 208000002249 Diabetes Complications Diseases 0.000 abstract description 2
- 206010012655 Diabetic complications Diseases 0.000 abstract description 2
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 2
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 210000003141 lower extremity Anatomy 0.000 description 10
- 210000001617 median nerve Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 208000034783 hypoesthesia Diseases 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 231100000862 numbness Toxicity 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 6
- 101100016586 Natronomonas pharaonis hcy gene Proteins 0.000 description 6
- 108091006374 cAMP receptor proteins Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 238000002567 electromyography Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 241000125175 Angelica Species 0.000 description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000020764 Sensation disease Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 210000000658 ulnar nerve Anatomy 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000015155 detection of stimulus involved in sensory perception Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Natural products CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 210000001590 sural nerve Anatomy 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application belongs to the field of traditional Chinese medicine formulas, and relates to a traditional Chinese medicine composition for treating qi deficiency and blood stasis syndrome of diabetic peripheral neuropathy, which comprises the following components of angelica sinensis, paeonia lactiflora, poria cocos, bighead atractylodes rhizome, rhizoma alismatis and ligusticum wallichii, and can be prepared into granules, powder, tablets, pills or capsules. The Chinese angelica, the Chinese herbaceous peony, the poria cocos, the bighead atractylodes rhizome, the rhizoma alismatis and the ligusticum wallichii are compatible, have the effects of replenishing qi, strengthening spleen and promoting diuresis, can be applied to the treatment of qi deficiency and blood stasis syndrome of diabetic peripheral neuropathy, can improve subjective symptoms of patients, has a certain improvement effect on sensory, motor disturbance and abnormal nerve conduction speed, has good compliance, has good curative effect on DPN qi deficiency and blood stasis syndrome, is safe and nontoxic, provides a basis for further popularization of traditional Chinese medicine for preventing and treating diabetic complications, and has good clinical application prospect and social benefit.
Description
Technical Field
The application belongs to the field of traditional Chinese medicine formulas, relates to a traditional Chinese medicine composition, and in particular relates to a traditional Chinese medicine composition for treating qi deficiency and blood stasis of diabetic peripheral neuropathy.
Background
Recent researches show that the prevalence rate and the incidence rate of diabetes mellitus in the global range are in a sharp rising trend, and the prevalence rate and the incidence rate of diabetes mellitus in the global range are obviously a global public health problem threatening human health. Diabetic peripheral neuropathy (diabetic peripheral neuropathy, DPN) is one of the most common complications of diabetes, the main clinical symptoms are lower limb distal symmetrical sensory disorder and dyskinesia, and can be accompanied with symptoms such as cold limbs, pain, numbness, hypodynamia and the like, the life quality of patients is seriously affected, and the incidence rate of DPN is increased along with the prolongation of the diabetes.
DPN belongs to the category of diabetes and flaccidity arthralgia in the theory of traditional Chinese medicine, and mainly takes qi deficiency, yin deficiency and yang deficiency as the principal, blood stasis and turbid phlegm as the principal, and blood stasis always penetrates through the whole course of DPN. For a long time, diabetes mellitus can cause blood vessel stasis due to deficiency of both qi and yin, deficiency of yang qi, weakness of qi and blood circulation, yin deficiency and blood stasis, and yang deficiency and blood coagulation; meanwhile, qi deficiency and yang deficiency, water dampness failing to resolve, blood stasis and stagnation of blood vessels can cause stagnation of damp evil. Therefore, peripheral neuropathy is combined in the later stage of diabetes, deficiency and excess are often mixed, and clinical observation shows that deficiency of qi, blood stasis and water are often manifested, leading to malnutrition of extremities. In recent years, with the continuous progress of medical level and the continuous increase of health requirements of people, prevention and treatment of DPN have become important subjects which cannot be ignored clinically. However, at present, no specific treatment method is provided for DPN, and the DPN mainly aims at symptomatic treatment such as vegetative nerve, metabolic disturbance improvement, pain relief and the like, has limited clinical effects, and has tolerance effect when relevant medicines are taken for a long time.
Disclosure of Invention
The application aims to provide a traditional Chinese medicine composition for treating qi deficiency and blood stasis of diabetic peripheral neuropathy, which is prepared from angelica sinensis, paeonia lactiflora, poria cocos, bighead atractylodes rhizome, rhizoma alismatis and ligusticum wallichii, has good curative effect when being applied to treatment of qi deficiency and blood stasis of diabetic peripheral neuropathy, can improve subjective symptoms of patients, has a certain improvement effect on sensory, motor disturbance and nerve conduction velocity abnormality, has economic, convenient and effective advantages, has definite social benefit, and is worthy of popularization and application.
The application adopts the technical scheme that:
a traditional Chinese medicine composition for treating diabetic peripheral neuropathy qi deficiency and blood stasis comprises the following components in parts by weight: 8-12 parts of Chinese angelica, 18-22 parts of Chinese herbaceous peony, 10-14 parts of poria cocos, 10-14 parts of bighead atractylodes rhizome, 12-16 parts of rhizoma alismatis and 12-16 parts of ligusticum wallichii.
Further, the traditional Chinese medicine composition for treating the qi deficiency and blood stasis syndrome of the diabetic peripheral neuropathy further comprises pharmaceutical excipients, wherein the pharmaceutical excipients are used for shaping, serving as carriers, improving stability, solubilizing, helping dissolution and the like, and preferably the pharmaceutical excipients are one or more of matrixes, absorption promoters, adhesives, excipients, disintegrants, fillers, lubricants, sweeteners, colorants and flavoring agents.
Further, the traditional Chinese medicine composition for treating the peripheral neuropathy qi deficiency and blood stasis of diabetes is prepared into granules, powder, tablets, pills or capsules after adding medicinal auxiliary materials.
Further, the traditional Chinese medicine composition for treating the qi deficiency and blood stasis of diabetic peripheral neuropathy is prepared into granules, and the preparation method is as follows:
mixing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma, and rhizoma Ligustici Chuanxiong according to a certain proportion, adding solvent, extracting, filtering, concentrating filtrate to obtain extract, mixing the extract with medicinal adjuvants, and granulating.
Further, the traditional Chinese medicine composition for treating the qi deficiency and blood stasis of diabetic peripheral neuropathy is prepared into powder, and the preparation method is as follows:
pulverizing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma, and rhizoma Ligustici Chuanxiong respectively, and sieving; mixing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma and rhizoma Ligustici Chuanxiong powder according to the ratio, adding medicinal adjuvants according to conventional technology (pharmacopoeia specification), and mixing to obtain powder.
Further, the traditional Chinese medicine composition for treating the qi deficiency and blood stasis of diabetic peripheral neuropathy is prepared into tablets, and the preparation method is as follows:
pulverizing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma, and rhizoma Ligustici Chuanxiong respectively, and sieving; mixing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma and rhizoma Ligustici Chuanxiong powder according to the ratio, adding medicinal adjuvants according to conventional technology (pharmacopoeia standard), mixing, pouring into a die of a tablet press, pressing, and oven drying the pressed Chinese medicinal tablet to obtain tablet.
The application is an oral medicine, which is taken with 1 dose/day 2 times/day with water, 1 hour before meal or 2 hours after meal with warm water.
The Chinese angelica, the Chinese herbaceous peony, the poria cocos, the bighead atractylodes rhizome, the rhizoma alismatis and the ligusticum wallichii are compatible, have the effects of replenishing qi, strengthening spleen and promoting diuresis, can be applied to the treatment of qi deficiency and blood stasis syndrome of diabetic peripheral neuropathy, can improve subjective symptoms of patients, has a certain improvement effect on sensory, motor disturbance and abnormal nerve conduction speed, has good compliance, has good curative effect on DPN qi deficiency and blood stasis syndrome, is safe and nontoxic, provides a basis for further popularization of traditional Chinese medicine for preventing and treating diabetic complications, and has good clinical application prospect and social benefit.
Detailed Description
The following describes the embodiments of the present application in further detail with reference to examples. The following examples are illustrative of the application and are not intended to limit the scope of the application. The experimental methods in the following examples are conventional methods unless otherwise specified. Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
1. Preparation of pharmaceutical formulations
Embodiment one, the Chinese medicinal composition is prepared into granules
According to the weight portions, 10 portions of angelica, 20 portions of paeonia, 12 portions of poria cocos, 12 portions of bighead atractylodes rhizome, 15 portions of rhizoma alismatis and 15 portions of ligusticum wallichii are taken, purified water is added for extraction, filtration and concentration of filtrate are carried out to obtain extract, the extract and conventional pharmaceutical auxiliary materials of the granule are uniformly mixed, the granule is prepared by adopting a granulating process, and the granule is packaged by an aluminum foil bag according to the total amount of the traditional Chinese medicine of 85+/-5 g.
In the second embodiment, the Chinese medicinal composition is prepared into powder
Pulverizing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma, and rhizoma Ligustici Chuanxiong respectively, and sieving; according to the weight portions, 9 portions of angelica powder, 18 portions of peony powder, 13 portions of poria cocos powder, 11 portions of bighead atractylodes rhizome powder, 13 portions of rhizoma alismatis powder and 14 portions of ligusticum wallichii powder are taken and mixed uniformly, conventional medicinal auxiliary materials of powder are added according to the standard operation of pharmacopoeia, the powder is obtained after uniform mixing, and the powder is packaged by an aluminum foil bag according to the total amount of 85+/-5 g of traditional Chinese medicines.
In embodiment III, the Chinese medicinal composition is formulated into tablet
Pulverizing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma, and rhizoma Ligustici Chuanxiong respectively, and sieving; according to the weight portions, 12 portions of angelica powder, 21 portions of peony powder, 10 portions of poria cocos powder, 14 portions of bighead atractylodes rhizome powder, 15 portions of rhizoma alismatis powder and 12 portions of ligusticum wallichii powder are taken, uniformly mixed, conventional pharmaceutical excipients of tablets are added according to the standard operation of pharmacopoeia, the mixture is poured into a mould for pressing after uniform mixing, the pressed traditional Chinese medicine tablets are dried to obtain tablets, and the tablets are packaged by aluminum foil bags according to the total amount of the traditional Chinese medicine of 85+/-5 g.
2. Safety evaluation
Safety indexes (vital signs, blood routine, urine, feces, liver and kidney functions, islet functions and other results) are detected during medication, adverse reaction events of a subject are recorded, and the judgment standards are as follows:
(1) Safety: no adverse reaction event occurs;
(2) The relative safety is as follows: the safety index is slightly abnormal, adverse reaction events occur but can be recovered by oneself, and the test progress is not influenced;
(3) The safety problem is that: the safety index is obviously abnormal;
(4) Serious adverse events occurred and the test terminated prematurely.
During the medication period of patients, the safety index detection shows that serious adverse events are not generated, only 1 subject takes the medicine and has dizziness symptoms, comprehensive analysis is related to cooling, and the medicine is released by oneself and continuously taken. The vital signs of other subjects are stable, and the safety index is not changed abnormally before and after the test.
3. Trial effects
A. A subject: among the diabetics who have been treated in 2019 to 2022, the patients who meet the symptoms of qi deficiency and blood stasis of peripheral neuropathy of diabetes are randomly divided into a treatment group (n=283), a control group (n=65) and a normal group (n=93) according to the principle of the random number method. The treatment groups are divided into three groups (96 persons in group I, 95 persons in group II and 92 persons in group III) which are treated by the medicaments obtained in the first, second and third embodiments of the application respectively; the control group is treated by the nutritional western medicine (Maikebao); the placebo drug (appearance, trait and Chinese medicinal composition) was administered to the conventional group (blank group).
B. The treatment method comprises the following steps: subjects in the treatment group participating in the observation study received the drug treatment obtained in example one, example two, example three; one dose (total amount of Chinese medicinal materials is 85+ -5 g) per day, 2 times per day, 1 hr before meal or 2 hr after meal. The subjects in the control group received the treatment of Western medicine Mikebao (produced by Wei Shao (China) pharmaceutical Co., ltd., 0.5 mg/tid oral administration). The subjects in the conventional group received placebo medication (the manufacturer of the medication provider and the method of administration were the same as in the treatment group). The treatment course is 1 month, and the follow-up is 3 months.
C. Evaluation of curative effect: the TCSS score and the Chinese medicine symptom score are respectively carried out on the subjects at two time points before and after the treatment, and all monitoring data are counted and analyzed by adopting SPSS22.0 software, so that the application can improve the feeling, the dyskinesia and the nerve conduction function of the patients with the peripheral neuropathy qi deficiency and blood stasis symptoms of diabetes through multiple targets and multiple ways, and compared with a control group and a conventional group, the difference has obvious significance.
1. Evaluation of clinical comprehensive efficacy
To identify the therapeutic effect of the subjects, the conditions before and after the treatment (before and after the intervention) of the subjects were observed, the number of significant effects and the number of effective effects were counted, and the total effective rate was calculated, and the results are shown in Table 1.
Table 1 comparison of clinical comprehensive efficacy evaluation
| Project | Number of cases | Number of apparent effects | Effective number | Number of invalidity | Total effective rate |
| Example one (group I) | 96 | 70 | 14 | 12 | 88％ |
| Example two (group II) | 95 | 65 | 15 | 15 | 84％ |
| Example III (group III) | 92 | 71 | 13 | 8 | 91％ |
| Control group | 65 | 25 | 15 | 25 | 62％ |
| Conventional group | 93 | 19 | 15 | 59 | 37％ |
The treatment results show that compared with the total effective rate of 62% of the control group and about 37% of the conventional group, the traditional Chinese medicine composition provided by the application has higher total effective rate (89%) for treating qi deficiency and blood stasis syndrome of diabetic peripheral neuropathy, and analysis of variance shows that the total effective rate of the traditional Chinese medicine composition is obviously higher than the value (P < 0.05) of the control group and the conventional group.
2. TCSS scoring conditions before and after intervention
To identify the treatment status of the subjects, the TCSS scores of the subjects before and after treatment (before and after intervention) were tested, and the TCSS score values before and after treatment were counted, and the results are shown in table 2.
TABLE 2 comparison of TCSS scores before and after intervention
Note that: Δtcss = post-intervention TCSS-pre-intervention TCSS; * : p <0.05, in contrast to the conventional group; #: p <0.05 compared to the control group.
The above results indicate that there is no statistical difference in TCSS score (P > 0.05) for subjects prior to intervention; in the dry state, the TCSS scores of the treatment group and the control group are reduced (P is less than 0.05) compared with the conventional group, and the TCSS scores of the treatment group are reduced more remarkably (P is less than 0.05) compared with the control group.
3. Scoring of symptoms of traditional Chinese medicine before and after intervention
To identify the treatment status of the subjects, the Chinese medicine symptoms before and after the treatment (before and after the intervention) of the subjects were scored, and the Chinese medicine symptom scoring values before and after the treatment were counted, and the results are shown in table 3.
TABLE 3 comparison of Chinese medical Condition scores before and after intervention
Note that: delta chinese medical science symptom score = post-intervention chinese medical science symptom score-pre-intervention chinese medical science symptom score; * : p <0.05, in contrast to the conventional group; #: p <0.05 compared to the control group.
The results show that the Chinese medicine symptoms of the subjects have no statistical difference (P > 0.05) compared with the scores before intervention; the dry prognosis has a decrease in Chinese medicine symptom score (P < 0.05) in both the treatment group and the control group compared with the conventional group, and has a more remarkable decrease in Chinese medicine symptom score (P < 0.05) in the treatment group compared with the control group.
4. Sensory conduction of median nerve before and after intervention
To identify the treatment condition of the subject, the sensory conduction function of the median nerve before and after the treatment (before and after the intervention) of the subject was observed, and the conduction speed, the conduction amplitude and the conduction latency were used as observation indexes, and the values of the conduction function before and after the intervention were counted, and the results are shown in tables 4, 5 and 6.
TABLE 4 comparison of sensory conduction velocity of median nerve before and after intervention
Note that: delta conduction velocity = post-intervention conduction velocity-pre-intervention conduction velocity; * : p <0.05 in comparison to the conventional group.
TABLE 5 median nerve sensory conduction amplitude comparison before and after intervention
Note that: delta conduction amplitude = post-intervention conduction amplitude-pre-intervention conduction amplitude.
TABLE 6 comparison of sensory conduction latency of median nerve before and after intervention
Note that: delta conduction latency = post-intervention conduction latency-pre-intervention conduction latency.
The results show that the difference of the sensory conduction functions of the median nerve of the subjects has no statistical significance (P is more than 0.05); after the dry state, the median nerve sensory transduction function of the treatment group was improved (P < 0.05) compared with the conventional group.
5. Serum related index conditions before and after intervention
To identify the treatment condition of the subjects, serum markers before and after the treatment (before and after the intervention) of the subjects are detected, IL-6, TNF-alpha, CRP and Hcy are taken as detection indexes, and the values of the serum IL-6, TNF-alpha, CRP and Hcy before and after the intervention are counted, so that the results are shown in tables 7, 8, 9 and 10.
TABLE 7 comparison of IL-6 before and after intervention
Note that: Δil-6 = post-dry IL-6-pre-intervention IL-6; * : p <0.05 in comparison to the conventional group.
TABLE 8 comparison of TNF- α before and after intervention
Note that: Δhcy = post-intervention TNF- α -pre-intervention TNF- α; * : p <0.05, in contrast to the conventional group; #: p <0.05 in comparison to the control group.
Table 9 CRP comparison before and after intervention
Note that: Δcrp = post-intervention CRP-pre-intervention CRP; * : p <0.05 in comparison to the conventional group.
Table 10 comparison of Hcy before and after intervention
Note that: Δhcy = post-intervention Hcy-pre-intervention Hcy; * : p <0.05 in comparison to the conventional group.
The above results indicate that the comparison differences between the serum IL-6, TNF-alpha, CRP, hcy expression levels of the subjects prior to intervention are statistically significant (P > 0.05); after the dry state, compared with the conventional group, the serum Hcy expression level of the subjects in the treatment group and the control group is reduced (P is less than 0.05); after the dry state, the IL-6 expression level of the subjects in the treatment group is reduced (P < 0.05) compared with the conventional group; after the dry state, compared with the conventional group and the control group, the serum TNF-alpha and CRP expression of the subjects in the treatment group is reduced (P is less than 0.05).
D. Brief description of treatment examples:
(1) Some men, 60 years old, have diabetes for 15 years and peripheral neuropathy for 3 years, and mainly show limb peripheral pain, numbness and sensory disturbance, listlessness, shortness of breath and laziness to talk, easy sweating and constipation, pale tongue with thin white coating, thready and astringent pulse and the like, and electromyography prompts right median nerve, ulnar nerve sensory nerve conduction to be normal and amplitude to be reduced; left and right sural superficial sensory nerve conduction velocity was normal and amplitude was reduced, conclusion was made that: peripheral nerve source damage of upper and lower limbs is mild (sensory fibers are affected). TCSS scores were evaluated as 11 points (moderate DPN) and chinese medical symptoms as moderate. For 3 years, patients repeatedly undergo western medicine nutrition nerve treatment, circulation improvement and other treatments, obvious curative effects are not achieved, and then the patients are treated by the Chinese medicinal composition in our hospital (1 dose/day 2 times/day of water infusion of 1 dose/day 2 hours before meals or 2 hours after meals, the treatment course is 1 month.1 month later, sensory disorders such as peripheral pain and numbness of limbs of the patients are improved, the TCSS and Chinese medicine symptom scores are reduced, and the electromyography prompts nerve conduction amplitude to be increased before, so that the nerve damage condition is improved.
(2) Some men, 58 years old, have a peripheral neuropathy of diabetes diagnosed by the outer hospital for more than 10 years, and mainly show a symmetrical burning sensation and a needling sensation at the far ends of the two lower limbs, and have a sock-like sensation, and have a tingling sensation and a stiff sensation; no lassitude, debilitation, normal sweating, stool adjustment, pale tongue with white and thick coating, deep pulse, etc. The electromyography prompts the right median nerve, the ulnar nerve and the sensory nerve to conduct at normal speed and the amplitude to decline; left sural nerve sensory nerve conduction velocity was normal and amplitude was reduced, conclusion was made that: moderate peripheral nerve-derived lesions of the upper and lower limbs (sensory and motor fibers affected). For many years, the physiotherapy such as VC and B6 intramuscular injection or oral mecobalamin nutrition nerve and ultrashort wave are not obviously improved, the illness state is repeated, thus, the treatment is carried out by the Chinese medicinal composition in the hospital (1 dose/day 2 times/day is carried out by taking Chinese angelica 10g of Chinese herbaceous peony 20g of poria cocos, 12g of rhizoma atractylodis macrocephalae 15g of rhizoma alismatis 15g of water, 1 hour before meal or 2 hours after meal with warm water, the treatment course is 1 month.1 month later, the symptoms of burning sensation of the two lower limbs, sock covering sensation and numbness and stiffness of the patient are obviously relieved before, the tongue is light red, the tongue is thin and white, the pulse is forceful, the electromyography indicates that the peripheral nerve source damage of the upper and lower limbs is mild, and the inflammation indexes such as serum IL-1, IL-6 and IL-8 of the patient are reduced before, and the nerve function recovery is possibly related to the inflammation index reduction.
(3) A woman, 52 years old, has no obvious cause before 11 years old, drinks 3-4 liters of water every day, has urination and urination amount of 2-3 liters every day, is diagnosed as type 2 diabetes in local hospitals, is a plain regular oral hypoglycemic drug, combines sports and diet, has stable blood sugar control, has no obvious cause for patients to have limb terminal numbness, takes a sock shape and symmetry, is accompanied with tingling feel, is usually at night, affects sleep, is tired, constipation, has dark red tongue and ecchymosis, and has thin and astringent pulse. The epalrestat tablet and the pentoxifylline sustained release tablet are taken throughout the year, the symptoms repeatedly occur, the patients see the doctor in the hospital and are treated by the traditional Chinese medicine composition (the same as the above), after 1 month, the symptoms of the patient are relieved by subjective numbness and stinging, and the biochemical indexes such as the re-examination homocysteine are reduced by the former. The traditional Chinese medicine composition is suggested to reduce vascular inflammation by reducing homocysteine so as to improve the nerve function.
(4) The method is characterized in that a woman is 50 years old, no obvious causes are caused before 8 years old, numbness of the two lower limbs is intermittent, sock feeling exists, the far end is obvious, the patient can visit a local hospital, after perfecting related examination, the diagnosis of type 2 diabetic peripheral neuropathy is carried out, the two lower limbs are numb usually, with ant feeling, coldness, pigmentation, easy to break, loose stool, clear and tired, pale tongue, tooth marks on the side, thin pulse, no importance and irregular treatment exist, the patient can visit the patient in me, the traditional Chinese medicine composition (same as above) is treated for 1 month, after 1 month, the patient complains about the two lower limb numbness, the number and degree of the attack of the ant feeling are obviously improved, the pigmentation of the two lower limbs becomes light, the stool is shaped, and no hypodynamia feeling exists.
The Chinese angelica, the Chinese herbaceous peony, the poria cocos, the bighead atractylodes rhizome, the rhizoma alismatis and the ligusticum wallichii are combined, a new thought is provided for standardized prevention and treatment of diabetic peripheral neuropathy qi deficiency and blood stasis, a multi-center multi-region combined research mode is adopted, modern scientific research technology is combined, powerful guarantee is provided for inheriting and developing traditional Chinese medicine culture, and the Chinese angelica preparation has innovative practical significance.
The foregoing is merely a preferred embodiment of the present application, and it should be noted that it will be apparent to those skilled in the art that several modifications and variations can be made without departing from the technical principle of the present application, and these modifications and variations should also be regarded as the scope of the application.
Claims (6)
1. A traditional Chinese medicine composition for treating diabetic peripheral neuropathy qi deficiency and blood stasis is characterized by comprising the following components in parts by weight: 8-12 parts of Chinese angelica, 18-22 parts of Chinese herbaceous peony, 10-14 parts of poria cocos, 10-14 parts of bighead atractylodes rhizome, 12-16 parts of rhizoma alismatis and 12-16 parts of ligusticum wallichii.
2. The traditional Chinese medicine composition according to claim 1, wherein: the traditional Chinese medicine composition also comprises a pharmaceutic adjuvant, wherein the pharmaceutic adjuvant is one or more of a matrix, an absorption accelerator, an adhesive, an excipient, a disintegrating agent, a filling agent, a lubricant, a sweetener, a colorant and a flavoring agent.
3. The traditional Chinese medicine composition according to claim 1, wherein: the traditional Chinese medicine composition is prepared into granules, powder, tablets, pills or capsules after adding medicinal auxiliary materials.
4. The traditional Chinese medicine composition according to claim 1, wherein: the traditional Chinese medicine composition is prepared into granules, and the preparation method is as follows:
mixing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma, and rhizoma Ligustici Chuanxiong according to a certain proportion, adding solvent, extracting, filtering, concentrating filtrate to obtain extract, mixing the extract with medicinal adjuvants, and granulating.
5. The traditional Chinese medicine composition according to claim 1, wherein: the traditional Chinese medicine composition is prepared into powder, and the preparation method is as follows:
pulverizing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma, and rhizoma Ligustici Chuanxiong respectively, and sieving; mixing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma and rhizoma Ligustici Chuanxiong powder according to the ratio, adding medicinal adjuvants according to conventional technology, and mixing to obtain powder.
6. The traditional Chinese medicine composition according to claim 1, wherein: the traditional Chinese medicine composition is prepared into tablets, and the preparation method is as follows:
pulverizing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma, and rhizoma Ligustici Chuanxiong respectively, and sieving; mixing radix Angelicae sinensis, radix Paeoniae, poria, atractylodis rhizoma, alismatis rhizoma and rhizoma Ligustici Chuanxiong powder according to a certain proportion, adding medicinal adjuvants according to conventional technology, mixing, pouring into a die of a tablet press, pressing, and oven drying the pressed Chinese medicinal tablet to obtain tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310552511.3A CN116920030A (en) | 2023-05-16 | 2023-05-16 | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy qi deficiency and blood stasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310552511.3A CN116920030A (en) | 2023-05-16 | 2023-05-16 | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy qi deficiency and blood stasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116920030A true CN116920030A (en) | 2023-10-24 |
Family
ID=88388471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310552511.3A Pending CN116920030A (en) | 2023-05-16 | 2023-05-16 | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy qi deficiency and blood stasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116920030A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724036A (en) * | 2004-07-20 | 2006-01-25 | 中山大学 | Medicine for improving internal secreting melatonin, and application of its related herb medicine |
| CN102727681A (en) * | 2012-06-20 | 2012-10-17 | 安徽中医学院 | Application of angelica peony powder in preparation of drugs for treating cirrhosis ascites |
| CN107961299A (en) * | 2016-10-19 | 2018-04-27 | 姜顺花 | A kind of Chinese medicine preparation for treating irregular menstruation |
| CN109498714A (en) * | 2018-12-19 | 2019-03-22 | 中山大学附属口腔医院 | Danggui shaoyao san |
-
2023
- 2023-05-16 CN CN202310552511.3A patent/CN116920030A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724036A (en) * | 2004-07-20 | 2006-01-25 | 中山大学 | Medicine for improving internal secreting melatonin, and application of its related herb medicine |
| CN102727681A (en) * | 2012-06-20 | 2012-10-17 | 安徽中医学院 | Application of angelica peony powder in preparation of drugs for treating cirrhosis ascites |
| CN107961299A (en) * | 2016-10-19 | 2018-04-27 | 姜顺花 | A kind of Chinese medicine preparation for treating irregular menstruation |
| CN109498714A (en) * | 2018-12-19 | 2019-03-22 | 中山大学附属口腔医院 | Danggui shaoyao san |
Non-Patent Citations (4)
| Title |
|---|
| SHI-GUANG QIU 等: "Protocol for evaluating the effects of Danggui Shaoyao Powder in the treatment of DPN with qi deficiency and blood stasis pattern based on routine therapy: a randomized controlled trial", CLINICAL RESEARCH COMMUNICATIONS, vol. 5, no. 2, 16 May 2022 (2022-05-16), pages 9 * |
| 徐志强等: "周青从虚从瘀论治糖尿病周围神经病变经验举隅", 山西中医, vol. 33, no. 04, 30 April 2017 (2017-04-30), pages 7 - 9 * |
| 方翔宇等: "加味当归芍药散联合常规治疗对气虚血瘀型 2 型糖尿病周围神经病变患者的临床疗效", 中成药, vol. 44, no. 6, 30 June 2022 (2022-06-30), pages 1820 - 1824 * |
| 郭建中等: "李发枝教授运用《金匮要略》当归芍药散治疗糖尿病并发症经验", 中医研究, vol. 29, no. 06, 30 June 2016 (2016-06-30), pages 36 - 39 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN102462834A (en) | Medicinal composition for controlling blood sugar of diabetic | |
| CN102631595B (en) | Medicament for treating II-type diabetes mellitus and preparation method thereof | |
| CN110833609A (en) | Traditional Chinese medicine composition for treating dyspepsia | |
| CN115770279A (en) | Traditional Chinese medicine composition for treating chronic lower limb venous diseases and decoction and preparation thereof | |
| CN111195310A (en) | Traditional Chinese medicine composition for treating hyperlipidemia | |
| CN116920030A (en) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy qi deficiency and blood stasis | |
| CN104548029A (en) | Pharmaceutical composition for treating epigastric pain | |
| CN112336802B (en) | Traditional Chinese medicine composition for improving glycolipidosis metabolism of diabetes and application thereof | |
| CN114272295B (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN102283993B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN108686094A (en) | A kind of Traditional Chinese medicine for decreasing blood sugar and preparation method thereof | |
| CN115154535B (en) | Traditional Chinese medicine compound for improving atherosclerosis and preparation method thereof | |
| CN102813875B (en) | Traditional Chinese medicine composition for treating lupus erythematosus as well as application thereof | |
| CN108066650B (en) | Traditional Chinese medicine compound composition with effect of treating metabolic syndrome and preparation method and application thereof | |
| CN114306497B (en) | Traditional Chinese medicine composition for treating kidney deficiency and blood stasis type osteoporosis, preparation and application | |
| CN116920047B (en) | Novel traditional Chinese medicine compound composition for treating myocardial injury related to coronavirus infection and preparation method thereof | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN1463734A (en) | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same | |
| CN105288410A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application of traditional Chinese medicine composition | |
| CN108175782B (en) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy | |
| CN1245184C (en) | Insomnia treating traditional Chinese medicine preparation and its preparing process | |
| CN1306830A (en) | Medicine for treating Type-11 diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |